Introduction {#s1}
============

Gastric cancer is one of the most aggressive tumors and tends to be associated with peritoneal dissemination, lymph node metastasis, and hematogenous metastasis. Although recent advances in its diagnosis and treatment have offered increased long-term survival for patients diagnosed at early stages of gastric cancer, the prognosis of advanced cancer remains dismal, with a 5-year survival rate of only 10--15% [@pone.0091842-Jemal1], [@pone.0091842-Jemal2]. A majority of patients with advanced disease die due to complications induced by metastasis but not the primary tumor [@pone.0091842-Valastyan1]. Recently, a series of rate-limiting steps have been proposed for tumor cells to become metastatic [@pone.0091842-Gupta1]. The multi-step processes consist of loss of cellular adhesion, local invasion, motility, angiogenesis, intravasation, circulation, extravasation, homing and the premetastatic niche, and organotropic colonization in specific organs [@pone.0091842-Lu1]. Therefore, identifying novel markers in the key steps of metastasis will help to predict recurrence and survival for patients in the early stages of gastric cancer.

Hypoxia has been reported to contribute directly to many critical aspects of cancer biology, including angiogenesis, epithelial-mesenchymal transition, invasion, metastasis, stem cell maintenance, energy metabolism, autocrine growth factor signaling, and refractory to targeted therapies [@pone.0091842-Majmundar1], [@pone.0091842-Keith1]. The best characterized hypoxia response pathway is mainly mediated through a transcription factor called hypoxia-inducible factor-1 (HIF-1α) [@pone.0091842-Semenza1]. Currently, the number of target genes, which are controlled by HIF-1α, is greater than 1000 and can be divided into the following five categories: transcription factors and histone modifiers; matrix degradation enzymes; receptor, receptor-associated kinases, and transporters; microRNA targets; and cell-adhesion molecules and membrane proteins [@pone.0091842-Semenza2], [@pone.0091842-Tsai1]. In addition, routine phase 1 and phase 4 clinical trials that target HIF-1α function or expression have been completed, including a pilot trial of oral Topotecan for the treatment of refractory advanced solid neoplasms expressing HIF-1α and the effects of Dutasteride on HIF-1α and vascular endothelial growth factor (VEGF) in the prostate (Clinical Trial: NCT00117013, NCT00880672; <http://clinicaltrials.gov/>). The positive results from these clinical trials have further reinforced the interest in drug development targeting HIF-1α signaling.

Despite the clinical development of anti-HIF-1α therapies, the prognostic and clinical value of HIF-1α overexpression in gastric cancer cells remains unclear. It is essential to explore whether tumors in which HIF-1α is overexpressed are associated with reduced survival. As the incidence and mortality rate of gastric cancer are extremely higher in Eastern Asian especially China, Japan and Korea, we present a meta-analysis evaluating the prognostic impact of one subset of proteins in HIF-1α signaling in gastric cancer patients in subgroup of different continents. We hope that our meta-analyses will provide a framework for hypoxia regulation of the metastasis cascade and further uncover the role of hypoxia/HIF-1α-regulated key target genes on the prognosis based on various steps of metastasis. Most importantly, the analyses of gene expression profiles on prognosis may lead to the development of clinical methods that can be used to predict the outcome of individual patients in a clinical setting.

Methods {#s2}
=======

Search strategy and selection criteria {#s2a}
--------------------------------------

The meta-analysis was performed by means of preferred reporting items for meta-analyses statement [@pone.0091842-Moher1], [@pone.0091842-McShane1]. The PUBMED, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure (CNKI) databases were searched (up until June 2013) without language restrictions. Various combinations of the following terms were used to screen for potentially related studies: "prognosis" and "survival" and "gastric" or "stomach" as well as "cancer" or "carcinoma" or "tumor".

Studies were included in the meta-analysis if they met the following criteria: (1) diagnosed gastric cancer and normal gastric epithelial mucosa in humans; (2) evaluated proteins by using immunohistochemistry (IHC) methods; (3) used Asian cohorts from medical centers, and (4) had a follow up time exceeding 5 years. The study selection was based on the association of proteins related to HIF-1α-mediated tumor metastasis signaling and prognosis. References of retrieved articles were cross-searched to identify any studies missed by the computerized literature search. Authors of eligible studies were contacted for additional data relevant to the meta-analysis. However, not all authors responded.

Data extraction and methodological assessment {#s2b}
---------------------------------------------

Data retrieved from all full publications included author, year of publication, country, antibody used for evaluation, and cut-off for diagnosis based on abnormal protein expression. In addition, data was collected on the number of readers, blinded readings, number of controls and cases, depth of invasion, lymph node status, distant metastasis, TNM stage, vascular invasion, histo-differentiation, tumor size, sex, and age of gastric cancer patients. Overall survival is defined as the time elapsed from surgery to death of patients with gastric cancer. In all cases, the data of interest for 5-year survival rates were extracted from Kaplan-Meier curves.

We tried to carefully avoid the duplication of data by examining each publication, the names of all authors, and the different medical centers involved. When an individual author published several articles obtained from the same or overlapping population, only the newest or most complete article was included in the analysis; otherwise independent data were analyzed. All data were extracted independently by three investigators (Chen J, Li T, and Liu XX), and any disparities were resolved by discussion.

Statistical analysis {#s2c}
--------------------

In the present study, we analyzed three categories of stratified models. The first stratified multivariate model was performed to confirm whether each protein was abnormally expressed in gastric cancer compared to the normal gastric mucosa. The second outcome of the meta-analysis was to measure the impact of aberrant protein expression on 5-year overall survival. The third model was used to examine the prognostic value of protein expression that was corrected by clinical variables, including sex, age, histo-differentiation, tumor size, depth of invasion, vascular invasion, lymph node status, distant metastasis, and TNM stage.

Based on clinical characteristics, the following variables were compared: T~1~ and T~2~ vs. T~3~ and T~4~; Stage I and Stage II, vs. Stage III and Stage IV; well and moderate differentiation vs. poor and undifferentiation; tumors larger than 5 cm in size vs. tumors less than 5 cm; and patients older than 60 years vs. patients younger than 60 years.

Data were combined to perform meta-analysis using STATA version 9.0, and a two-tailed p-value of less than 0.05 was considered to be statistically significant. Estimates of risk ratios (RRs) or odds ratios (ORs) were weighted and pooled using different models based on their extent of heterogeneity. The heterogeneity across studies was quantified by using the I^2^ statistic, which is generally considered significant for values ≥50%. In the case of heterogeneity, meta-analysis was performed using the random effects model after exploring the causes of heterogeneity. Otherwise, the fixed-effects model was applied. In addition, one-way sensitivity analysis was conducted to assess the stability of the results, namely, a single study in the meta-analysis was deleted one at a time to check the influence of the individual data set on the pooled RR (or OR) [@pone.0091842-Lau1], [@pone.0091842-LouQian1]. Both Begg\'s funnel plot and Egger\'s test were used to determine any publication bias for each of the pooled study groups.

Results {#s3}
=======

Study selection and characteristics {#s3a}
-----------------------------------

After screening a collection of publications on proteins associated with hypoxia regulation of the metastasis cascade and prognosis, we identified 73 studies that used IHC techniques to assess the expression of four proteins on our prior criteria in the search strategy and study selection. Of these, 17 studies evaluated HIF-1α (from Liu et al., 2004 to Hoon Hur, et al., 2013), 20 studies evaluated phosphatase and tensin homolog (PTEN) (from Li et al., 2003 to Hye Seung Lee et al., 2003), 20 studies evaluated Survivin (from Yu et al., 2002 to Min A Kim et al., 2011), and 16 studies evaluated CD44v6 (from Xin et al., 2001 to Dae-Woon Eom et al., 2011) ([Fig. 1](#pone-0091842-g001){ref-type="fig"}, [Table 1](#pone-0091842-t001){ref-type="table"}). The median age of patients was 57.7 years old. The main characteristics of included studies are shown in [Table 1](#pone-0091842-t001){ref-type="table"} and [Table S1](#pone.0091842.s001){ref-type="supplementary-material"}, and the publications used to perform meta-analyses are listed in the [References S1](#pone.0091842.s002){ref-type="supplementary-material"}.

![Flow chart of the meta-analysis.](pone.0091842.g001){#pone-0091842-g001}
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###### Main characteristics of the 73 studies included in the final meta-analyses.
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  First author                       Language   Race    Study   Number                    Cutoff   Protein                 Antibody                                                   
  -------------------------- ------ ---------- ------- ------- --------- ------ -------- -------- --------- -------------------------------------- ----- ---- ------------------ ---- ----------
  Liu, et al                  2004   Chinese    China    No       \-       \-    1:100      \-      63.3%             Rb, Boster Biotech            \-    \-          \-          \-      \-
  Chen, et al                 2005   English    China    Yes     34/28     \-     1:50    \>10%      \-             H-206, Santa Cruz, CA           \-    \-          \-          \-      \-
  Han, et al                  2006   Chinese    China    Yes     58/38    61.5    1:50    \>10%     80.2%           MS-1164-P0, NeoMarkers          \-    \-   Reported in text   OS   Positive
  Ru, et al                   2007   Chinese    China    Yes     86/32    57.6     \-     \>10%      \-                       \-                    Yes   2    Reported in text   OS   Positive
  Wu, et al                   2009   Chinese    China    Yes     34/18     58      \-     \>10%     53.9%            Rb, Boshide Biotech            \-    \-          \-          \-      \-
  Qiu, et al                  2011   English    China    Yes    127/61     57     1:50      \-      58.5%           MS-1164-P0, NeoMarkers          Yes   2    Reported in text   OS   Positive
  Wang, et al                 2010   English    China    Yes     59/21     \-    1:200    \>10%      \-                  MS, Chemicon               \-    \-          \-          \-      \-
  Jia, et al                  2013   English    China    Yes    117/56     62     1:50    \>10%      \-               MS, Santa Cruz, CA            Yes   2           \-          \-      \-
  Lu, et al                   2013   English    China    Yes     43/25    49.9   1:100     \>6%      \-              MS, MAB1935 R and D            Yes   2    Reported in text   OS   Negative
  KEN MIZOKAMI, et al         2006   English    Japan    Yes     85/41    65.2   1:100    \>10%     38.9%     NB 100-105, Novus Biologicals, CO     Yes   2    Reported in text   OS   Positive
  Yasushi Sumiyashi, et al    2006   English    Japan    Yes    148/68    65.2   1:100    \>10%     39.4%     NB 100-105, Novus Biologicals, CO     Yes   2    Reported in text   OS   Positive
  NaoMI URANO, et al          2006   English    Japan    Yes      \-       \-     1:50    \>10%      \-         H1α 67, Novus Biologicals, CO       \-    \-   Reported in text   OS   Negative
  Yanislav Kolev, et al       2008   English    Japan    Yes    110/42    59.5   1:500    \>10%     62.5%                MS, MAB 5382               Yes   2    Reported in text   OS   Negative
  JUN Nakamura, et al         2009   English    Japan    Yes     43/20    66.9   1:200    \>10%     57.1%     NB 100--105, Novus Biologicals, CO    \-    \-   Reported in text   OS   Positive
  Taro Isobel, et al          2012   English    Japan    Yes     91/37    67.3    1:50     \>5%      \-             H-206, Santa Cruz, CA           \-    \-   Reported in text   OS   Positive
  SunYong Oh, et al           2008   English    Korea    Yes     67/47     59     1:50     \>1%      \-         H1α 67, Novus Biologicals, CO       \-    \-   Reported in text   OS   Positive
  Hoon hur, et al             2013   English    Korea    Yes     96/56     \-     1:50     \>5%      \-          Thermo Fisher Scientific, CA       Yes   2    Reported in text   OS   Negative
  Li, et al                   2003   Chinese    China    No      70/30     56      \-     \>10%      \-               Rb, Boster Biotech            \-    \-   Reported in text   OS   Positive
  Yang, et al                 2003   English    China    Yes      \-       \-      \-      \>5%     52.2%             Rb, Maixim Biotech            \-    \-          \-          \-      \-
  Zheng, et al                2003   English    China    Yes     83/30    57.1     \-      \>5%     45.1%            Antibody Dignostica            Yes   2           \-          \-      \-
  Li, et al                   2004   Chinese    China    Yes      \-       \-      \-      \>5%     70.2%             MS, Maixim Biotech            \-    \-          \-          \-      \-
  Deng, et al                 2006   English    China    Yes     99/41     58      \-       \-       \-             Clone 17A, NeoMarkers           \-    \-          \-          \-      \-
  Li, et al                   2007   Chinese    China    Yes    112/56     63      \-      \>5%     53.0%             MS, Maixim Biotech            \-    \-   Reported in text   OS   Positive
  Wang, et al                 2008   English    China    No      73/39    49.4     \-       \-      62.5%         Shanghai Changdao Biotech         Yes   2           \-          \-      \-
  Guo, et al                  2008   English    China    Yes     41/12    65.6     \-     \>10%     34.0%                     \-                    \-    \-          \-          \-      \-
  Wu, et al                   2011   English    China    Yes      \-       \-      \-       \-       \-             Zymed Laboratories Inc          Yes   2    Reported in text   OS   Negative
  Liang, et al                2012   English    China    Yes     55/26    55.4   1:100    \>10%      \-           Clone 28H6, Invitrogen Co         Yes   2    Reported in text   OS   Positive
  Yang, et al                 2012   English    China    Yes     23/20     \-    1:150     \>5%     60.0%               ab31392, Abcam              Yes   2           \-          \-      \-
  Li, et al                   2012   English    China    Yes     15/18    51.6     \-     \>10%     54.6%             MS, Maixim Biotech            Yes   3           \-          \-      \-
  Bai, et al                  2013   English    China    Yes    170/58    60.7     \-     \>10%      \-                       \-                    Yes   2    Reported in text   OS   Positive
  Zhu, et al                  2013   English    China    Yes    112/47     65     1:50     \>5%     61.6%             Ms, Santa Cruz, CA            Yes   3           \-          \-      \-
  Zheng, et al                2007   English    Japan    Yes    177/72    66.6   1:200     \>5%     27.7%         NovoCastro, Newcastle, UK         Yes   3    Reported in text   OS   Positive
  Rumi Hino, et al            2009   English    Japan    Yes     65/29     \-    1:100    \>10%      \-               MS, Santa Cruz, CA            \-    \-          \-          \-      \-
  Young-Hwa Kang, et al       2002   English    Korea    Yes    212/98    54.4   1:200    \>10%     20.0%              MS, AG Science,              \-    \-   Reported in text   OS   Positive
  Seock Ah Im, et al          2003   English    Korea    Yes     52/42     59    1:100    \>10%      \-             MS, Neomarker, Fremont          \-    \-   Reported in text   OS   Positive
  Geun Soo Park, et al        2005    Korean    Korea    Yes     57/33     \-    1:200    \>10%      \-             NeoMarkers, Union, CA           \-                \-          \-      \-
  Hye Seung Lee, et al        2003   English    Korea    Yes      \-      54.8    1:50    \>10%      \-                 San Diego, CA               \-    \-   Reported in text   OS   Positive
  Yu, et al                   2002   English    China    Yes     33/17    62.2   1:200     \>5%     58.3%      Novus Biologicals, Littleton, CA     Yes   2           \-          \-      \-
  Zhu, et al                  2003   English    China    Yes     46/10    59.8     \-       \-      48.2%                     \-                    \-    \-          \-          \-      \-
  Sun, et al                  2003   Chinese    China    No      96/44    55.5     \-      \>5%      \-                 MS, NeoMarkers              \-    \-   Reported in text   OS   Positive
  Yao, et al                  2004   Chinese    China    Yes     72/48    64.8    1:50     \>5%      \-                 MS, NeoMarkers              \-    \-          \-          \-      \-
  Li, et al                   2004   English    China    Yes     56/24     60      \-      \>5%     76.3%               MS, NeoMarkers              \-    \-          \-          \-      \-
  Lu, et al                   2004   Chinese    China    Yes     20/12     56      \-     \>10%     62.5%             MS, Santa Cruz, CA            \-    \-          \-          \-      \-
  Deng, et al                 2006   English    China    Yes     99/41     58      \-       \-       \-              RAB-0536, NeoMarkers           \-    \-          \-          \-      \-
  Sun, et al                  2006   Chinese    China    Yes     73/24     55    1:100    \>10%     60.8%             MS, Boster Biotech            \-    \-   Reported in text   OS   Positive
  Cheng, et al                2007   English    China    Yes     29/24     \-      \-       \-      100%              MS, Boster Biotech            \-    \-          \-          \-      \-
  Han, et al                  2007   English    China    Yes      \-       \-     1:80      \-      100%              Rb, Santa Cruz, CA            Yes   2           \-          \-      \-
  Deng, et al                 2010   English    China    Yes     37/16     55     1:50     \>5%     73.6%         Rb, Jingmei Biotechnology         Yes   2    Reported in text   OS   Positive
  Li, et al                   2010   English    China    Yes     38/27    56.2   1:100     \>5%      \-               Rb, Santa Cruz, CA            Yes   2           \-          \-      \-
  Meng, et al                 2012   English    China    Yes     67/23     \-      \-      \>5%      \-               Rb, Santa Cruz, CA            \-    \-   Reported in text   OS   Positive
  Deng, et al                 2012   English    China    Yes     60/23     58      \-       \-       \-              RAB-0536, NeoMarkers           \-    \-          \-          \-      \-
  Cai De Lu, et al            1998   English    Japan    Yes    124/50    59.7     \-      \>5%     34.5%                     \-                    \-    \-          \-          \-      \-
  Rumi Hino, et al            2008   English    Japan    Yes     84/33     \-    1:500    \>10%      \-              MS, LSAB2 Kit, Dako            \-    \-          \-          \-      \-
  Hirokazu Okayama, et al     2009   English    Japan    Yes     91/44    63.4   1:1000     \-       \-      Rb, Novus Biologicals, Littleton, CO   Yes   2           \-          \-      \-
  Gi-Hoon Lee, et al          2006   English    Korea    Yes     74/32    58.9   1:500    \>10%     50.0%              R&D Systems Inc              Yes   2    Reported in text   OS   Positive
  Kyo Yong Song, et al        2009   English    Korea    Yes    102/55    57.8   1:1000             40.1%    Rb, Novus Biologicals, Littleton, CO   Yes   2    Reported in text   OS   Positive
  Min A Kim, et al            2011   English    Korea    Yes    774/388    \-    1:400    \>10%      \-                R&D Systems Inc              \-    \-          \-          \-      \-
  Xin, et al                  2001   English    China    Yes      \-       \-    1:200     \>5%     40.7%              R&D Systems Inc              Yes   2           \-          \-      \-
  Li, et al                   2003   Chinese    China    Yes     81/29    52.5     \-      \>5%      \-               MS, Santa Cruz, CA            \-    \-   Reported in text   OS   Positive
  Chen, et al                 2004   English    China    Yes     26/17    58.5     \-     \>10%      \-               MS, Maixin Biotech            \-    \-          \-          \-      \-
  Zhao, et al                 2005   Chinese    China    Yes     27/13     52      \-      \>5%      \-            MS, Jinshan Biotech, CA          \-    \-          \-          \-      \-
  Liu, et al                  2005   English    China    Yes     26/14     \-      \-       \-      62.5%                     \-                    \-    \-          \-          \-      \-
  Lou, et al                  2005   English    China    Yes      \-       41      \-      \>5%     79.0%             Boster Biotech, CA            \-    \-          \-          \-      \-
  Han, et al                  2007   English    China    Yes      \-       \-    1:100      \-      83.9%                   MS, -                   Yes   2           \-          \-      \-
  Zhou, et al                 2007   Chinese    China    Yes     72/31     56    1:100    \>10%     60.2%           Zhongshan, Biotech, CA          \-    \-   Reported in text   OS   Negative
  Liang, et al                2012   English    China    Yes     38/21    61.8     \-      \>5%     64.4%                   MS, -                   \-    \-          \-          \-      \-
  Ru, et al                   2012   English    China    Yes     36/9     62.6     \-       \-       \-               MS, Maixin Biotech            Yes   2           \-          \-      \-
  Kazushi Kurozumi, et al     1998   English    Japan    Yes     68/30     61      \-       \-      69.4%                     \-                    \-    \-          \-          \-      \-
  Hiroaki Saito, et al        1998   English    Japan    Yes     75/42    62.6     \-      \>5%      \-                       \-                    \-    \-   Reported in text   OS   Positive
  Akio Yamaguchi, et al       2002   English    Japan    Yes      \-       \-      \-       \-       \-                       \-                    Yes   2    Reported in text   OS   Positive
  Hirokazu Okayama, et al     2009   English    Japan    Yes     91/44    63.4   1:100     \>5%     62.2%              R&D Systems Inc              Yes   2           \-          \-      \-
  MeeJoo, et al               2003   English    Korea    Yes     59/40    57.6     \-     \>10%     68.7%          Clone, DF1485, Biogenex          \-    \-          \-          \-      \-
  Dae-Woon Eom, et al         2011   English    Korea    Yes     54/18     62      \-     \>10%      \-                       \-                    \-    \-   Reported in text   OS   Positive

Pub, publication; Exp, expression; RR, risk ratio; OS, overall survival; Positive, inverse relationship between specific protein expression and survival; Negative, no relationship. 'Reader' are readers of the histologic slides, 'blinded reading' means that readers of the slides without knowledge of the clinical outcome, and '−' corresponds to missing data.

Evaluation and expression of four specific proteins {#s3b}
---------------------------------------------------

Various antibodies were used to assess HIF-1α/PTEN/CD44v6 /Survivin expression. Among the group determined as HIF-1α-overexpressed, five studies used antibody NB-100-105 (Novus Biologicals; CA) and three studies used antibody H-206 (Santa Cruz Biotechnologies; CA) ([Table 1](#pone-0091842-t001){ref-type="table"}). The cut-off points for overexpression of HIF-1α selected in most studies was 10% in terms of antibody dilution ranging from 1∶50 to 1∶100 ([Table 1](#pone-0091842-t001){ref-type="table"}). The median frequency for the subset of proteins expressed in gastric cancer was 54.1% (range, 38.9--80.2%) for HIF-1α, 61.2% (range, 40.7--3.9%) for CD44v6, 55.6% (range, 34.5--76.3%) for Survivin, and 43.3% (range, 20.0--70.2%) for PTEN. A description of the antibodies used in the included studies is shown in [Table 1](#pone-0091842-t001){ref-type="table"}.

Meta-analysis results {#s3c}
---------------------

### Correlation of HIF-1α expression between gastric cancer and normal gastric mucosa {#s3c1}

Our analyses, combining 8 independent studies that included 923 patients and 898 controls, revealed that HIF-1α overexpression was frequently observed in patients with gastric cancer compared to the counterpart normal tissue. The OR was 272.194 (95% confidence interval (CI) 99.702--743.112, P\<0.001), without any heterogeneity between studies (I^2^ = 0.00%, subgroup difference P = 0.920) ([Table 2](#pone-0091842-t002){ref-type="table"}).

10.1371/journal.pone.0091842.t002

###### Meta-analyses of HIF-1α/PTEN/CD44v6/Survivin expressions on gastric cancer.
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  Stratification of gastric cancer    HIF-1α        PTEN                                                                                                                                           
  ---------------------------------- -------- ---- ------ -------- ---------------------------- ------- -------- ------- ------- ---- ------ -------- --------------------------- ------- -------- -------
  Case-Control                        China    4    707    Fixed    283.675 (68.842--1168.933)   0.000   0.00%    0.096   China   9    1660   Random    18.197 (10.201--32.462)    0.000   57.10%  
                                      Japan    4    1114   Fixed    263.152 (64.237--1078.016)   0.000   0.00%            Japan   1    382      \-       3.538 (1.873--6.684)      0.000     .%    
                                      Korea    \-    \-      \-                 \-                \-       \-             Korea   1    620      \-     156.187 (9.614--2537.471)   0.000     .%    
                                       All     8    1821   Fixed    272.194 (99.702--743.112)    0.000   0.00%             All    11   2662   Random    16.930 (8.613--33.280)     0.000   75.00%   0.034
  Overall 5-year survival             China    3    350    Fixed       1.486 (1.191--1.855)      0.000   0.00%    0.331   China   5    605    Random     1.532 (1.309--1.792)      0.000   59.20%  
                                      Japan    5    717    Fixed       1.554 (1.264--1.911)      0.000   21.20%           Japan   1    232      \-       1.645 (1.275--2.123)      0.000     .%    
                                      Korea    2    266    Random      1.428 (1.072--1.902)      0.015   87.00%           Korea   3    714    Fixed      1.839 (1.424--2.376)      0.000   0.00%   
                                       All     10   1333   Fixed       1.508 (1.318--1.725)      0.000   35.30%            All    9    1551   Fixed      1.637 (1.452--1.845)      0.000   40.60%   0.006
  The depth of invasion               China    4    452    Fixed       5.046 (2.867--8.880)      0.000   35.70%   0.017   China   9    956    Random     1.862 (1.036--3.346)      0.038   62.30%  
                                      Japan    4    622    Fixed       1.926 (1.384--2.680)      0.000   0.00%            Japan   1    249      \-       5.085 (2.698--9.586)      0.000     .%    
                                      Korea    1    114      \-       4.231 (1.482--12.079)      0.007     .%             Korea   2    394    Fixed      6.149 (3.135--12.062)     0.000   0.00%   
                                       All     9    1188   Random      3.050 (2.067--4.501)      0.000   53.80%            All    12   1599   Random      2.604(1.554--4.366)      0.000   69.00%   0.909
  Lymph node status                   China    6    683    Random      3.814 (2.703--5.382)      0.000   59.30%   0.060   China   13   1410   Random     2.499 (1.704--3.665)      0.000   52.60%  
                                      Japan    4    618    Fixed       3.195 (2.248--4.542)      0.000   0.00%            Japan   2    364    Random     3.010 (1.250--7.251)      0.014   60.20%  
                                      Korea    1    114      \-       3.276 (0.888--12.084)      0.075     .%             Korea   3    484    Random     2.136 (0.988--4.617)      0.054   62.90%  
                                       All     11   1415   Fixed       3.486 (2.737--4.440)      0.000   31.40%            All    18   2258   Random     2.484 (1.836--3.360)      0.000   51.50%   0.583
  Distant metastasis                  China    4    341    Random     6.617 (1.273--34.391)      0.025   79.90%   0.711   China   5    650    Fixed      2.947 (1.605--5.411)      0.01    0.00%   
                                      Japan    1    128      \-       6.563 (1.457--29.551)      0.014     .%             Japan   1    249      \-       8.345 (2.558--27.218)     0.000     .%    
                                      Korea    \-    \-      \-                 \-                \-       \-             Korea   3    494    Fixed      1.485 (0.803--2.746)      0.207   47.40%  
                                       All     5    469    Random     6.635 (1.855--23.738)      0.004   73.30%            All    9    1393   Fixed      2.528 (1.703--3.751)      0.000   35.30%   0.818
  TNM stage                           China    6    665    Fixed       3.602 (2.439--5.320)      0.000   21.30%   0.068   China   8    904    Fixed      2.019 (1.247--3.267)      0.004   44.70%  
                                      Japan    3    495    Fixed       1.602 (1.097--2.338)      0.015   0.00%            Japan   1    115      \-       3.339 (1.131--9.858)      0.029     .%    
                                      Korea    1    110      \-       4.231 (1.482--12.079)      0.007     .%             Korea   3    494    Random     2.838 (1.280--6.291)      0.01    69.80%  
                                       All     10   1274   Fixed       2.762 (1.941--3.942)      0.000   48.40%            All    12   1513   Random     2.345 (1.601--3.435)      0.000   50.50%   0.858
  Vascular invasion                   China    2    180    Fixed      5.275 (2.287--12.167)      0.000   0.00%    0.142   China   \-    \-      \-                \-                \-       \-    
                                      Japan    4    618    Fixed       2.002 (1.413--2.836)      0.000   18.40%           Japan   \-    \-      \-                \-                \-       \-    
                                      Korea    \-    \-      \-                 \-                \-       \-             Korea   \-    \-      \-                \-                \-       \-    
                                       All     6    798    Fixed       2.368 (1.725--3.252)      0.000   43.50%            All    \-    \-      \-                \-                \-       \-      \-
  Histological differentiation        China    6    703    Fixed       1.684 (1.055--2.686)      0.029   47.80%   0.094   China   11   1164   Fixed      2.035 (1.577--2.627)      0.000   35.70%  
                                      Japan    4    621    Random      2.941 (1.463--5.914)      0.002   75.50%           Japan   \-    \-      \-                \-                \-       \-    
                                      Korea    \-    \-      \-                 \-                \-       \-             Korea   2    400    Fixed      0.954 (0.594--1.533)      0.846   0.00%   
                                       All     10   1324   Random      2.112 (1.410--3.163)      0.000   64.10%            All    13   1564   Fixed      1.715 (1.371--2.145)      0.000   48.00%   0.258
  Size                                China    4    522    Random      2.118 (1.468--3.056)      0.000   74.40%   0.945   China   2    162    Fixed      2.197 (1.071--4.506)      0.032   55.20%  
                                      Japan    1    152      \-        1.404 (0.724--2.722)      0.315     .%             Japan   1    249      \-       3.063 (1.685--5.566)      0.000     .%    
                                      Korea    \-    \-      \-                 \-                \-       \-             Korea   1     90      \-       1.078 (0.461--2.524)      0.862     .%    
                                       All     5    674    Random      1.921 (1.395--2.647)      0.000   68.80%            All    4    501    Fixed      2.188 (1.468--3.259)      0.000   50.90%   0.950
  Sex                                 China    3    330    Fixed       1.102 (0.707--1.719)      0.667   44.40%   0.883   China   8    846    Fixed      1.371 (1.005--1.869)      0.046   21.30%  
                                      Japan    3    406    Random      0.750 (0.499--1.126)      0.165   53.90%           Japan   2    364    Fixed      1.584 (0.903--2.780)      0.109   0.00%   
                                      Korea    1    114      \-        1.043 (0.381--2.853)      0.935     .%             Korea   2    400    Fixed      1.468 (0.877--2.459)      0.144   0.00%   
                                       All     7    850    Fixed       0.905 (0.679--1.205)      0.495   37.10%            All    12   1610   Fixed       1.431(1.126--1.818)      0.003   0.00%    0.359
  Age                                 China    6    667    Fixed       0.741(0.529--1.040)       0.083   0.00%    0.920   China   7    687    Fixed      1.533 (1.107--2.124)      0.01    57.20%  
                                      Japan    4    622    Fixed       0.976 (0.686--1.388)      0.891   37.20%           Japan   2    364    Fixed      1.363 (0.803--2.313)      0.251   0.00%   
                                      Korea    1    114      \-        0.855 (0.310--2.360)      0.763     .%             Korea   1     90      \-       1.571 (0.670--3.685)      0.299     .%    
                                       All     11   1403   Fixed       0.846 (0.667--1.072)      0.166   0.00%             All    10   1141   Fixed      1.494 (1.148--1.944)      0.003   36.40%   0.970

NS, number of studies, NP, number of patients; OR, odd ratio; RR, risk ratio; CI, confidence interval.

### Correlation of HIF-1α expression with 5-year overall survival {#s3c2}

Meta-analysis on the prognostic value of HIF-1α expression showed that the overall survival rate at 5 years after the initial treatment was significantly lower in cases with overexpressed HIF-1α in 10 studies (1333 patients). The combined RR was 1.508 (95% CI  = 1.318--1.725; P\<0.001), with low heterogeneity in the data (I^2^ = 35.3%, subgroup difference P = 0.126) ([Fig. 2](#pone-0091842-g002){ref-type="fig"}, [Table 2](#pone-0091842-t002){ref-type="table"}). When stratifying for ethnicity, results were similar among patients from China, Japan, and Korea ([Fig. 2](#pone-0091842-g002){ref-type="fig"}, [Table 2](#pone-0091842-t002){ref-type="table"}).

![Meta-analysis on the relation between HIF-1α expression and 5-year overall survival (OS).\
The summary RR and 95% CIs were shown (fixed-effect model analysis).](pone.0091842.g002){#pone-0091842-g002}

### Correlation of HIF-1α expression with clinical variables {#s3c3}

When stratifying clinicopathological variables by the depth of invasion of gastric cancer, statistical significance was observed. Patients with T~3~ and T~4~ gastric cancer had higher HIF-1α expression in 9 studies (1188 patients; OR  = 3.050, 95% CI  = 2.067--4.501, P\<0.001) than those with T~1~ and T~2~ gastric cancer, with moderate between-study heterogeneity (I^2^ = 53.8%, subgroup difference P = 0.027) ([Table 2](#pone-0091842-t002){ref-type="table"}). When stratifying for the lymph node status of gastric cancer, the results showed that overexpressed HIF-1α was significantly associated with lymph node metastasis in 11 studies (1415 patients; OR  = 3.486, 95% CI  = 2.737 --4.440, P\<0.001), with low heterogeneity among studies (I^2^ = 31.4%, subgroup difference P = 0.148) ([Table 2](#pone-0091842-t002){ref-type="table"}). When stratifying for vascular invasion status, the overexpression of HIF-1α showed a significant association with the presence of vascular invasion in 6 studies (798 patients; OR  = 2.368, 95% CI  = 1.725--3.252, P\<0.001), with low between-study heterogeneity (I^2^ = 43.5%, subgroup difference P = 0.115) ([Table 2](#pone-0091842-t002){ref-type="table"}). When stratifying the distant metastasis of gastric cancer, HIF-1α expression was significantly associated with distant metastasis in 5 studies (469 patients; OR  = 6.635, 95% CI  = 1.855--23.738, P = 0.004), although, with evident between-study heterogeneity (I^2^ = 73.3%, subgroup difference P = 0.005) ([Table 2](#pone-0091842-t002){ref-type="table"}). When further stratifying the TNM stage, HIF-1α expression of patients with stages III and IV gastric cancer was much higher than those with stage I and II gastric cancer in 10 studies (1274 patients; OR  = 2.762, 95% CI  = 1.941--3.942, P\<0.001), without significant between-study heterogeneity (I^2^ = 48.4%, subgroup difference P = 0.042) ([Table 2](#pone-0091842-t002){ref-type="table"}).

We also observed a correlation between overexpressed HIF-1α with poor histological differentiation in 10 studies (1324 patients) because the pooled ORs (95% CI) were 2.112 (1.410--3.163, P\<0.001) and the tumor size was 1.921 (1.395--2.647, P\<0.001), but not for sex (0.905; 0.679--1.205, P = 0.495) and age (0.846; 0.667--1.072, P = 0.166), among all Asian patients ([Table 2](#pone-0091842-t002){ref-type="table"}).

### Correlation of PTEN expression with prognosis {#s3c4}

The combined results showed that PTEN expression in Asian patients with gastric cancer was significantly lower than controls among 11 studies (1498 patients and 1164 controls; OR  = 16.930, 95% CI  = 8.613--33.280, P\<0.001) ([Table 2](#pone-0091842-t002){ref-type="table"}). Reduced PTEN expression correlated with poor overall survival in 9 studies (1551 patients; RR  = 1.637, 95% CI  = 1.452--1.845, P\<0.001) ([Fig. 3](#pone-0091842-g003){ref-type="fig"} and [Table 2](#pone-0091842-t002){ref-type="table"}). Subgroup analysis showed a trend that reduced PTEN levels were associated with the following factors: depth of invasion (12 studies, 1599 patients; OR  = 2.604, 95% CI  = 1.554--4.366, P\<0.001); lymph node metastasis (18 studies, 2258 patients; OR  = 2.484, 95% CI  = 1.836--3.360, P\<0.001); distant metastasis (9 studies, 1393 patients; OR  = 2.528, 95% CI  = 1.703--3.751, P\<0.001); TNM stage; 12 studies, 1513 patients; OR  = 2.345, 95% CI  = 1.601--3.435, P\<0.001); histological differentiation (13 studies, 1564 patients; OR  = 1.715, 95% CI  = 1.371--2.145, P\<0.001); tumor size (4 studies, 501 patients; OR  = 2.188, 95% CI  = 1.468--3.259, P\<0.001); sex (12 studies, 1610 patients; OR  = 1.431, 95% CI  = 1.126--1.818, P = 0.003); and age (10 studies, 1141 patients; OR  = 1.494, 95% CI  = 1.148--1.944, P = 0.003) ([Table 2](#pone-0091842-t002){ref-type="table"}).

![Meta-analysis on the relation between PTEN expression and 5-year overall survival (OS).\
The summary RR and 95% CIs were shown (fixed-effect model analysis).](pone.0091842.g003){#pone-0091842-g003}

### Correlation of CD44v6 expression with prognosis {#s3c5}

A similar result was observed for CD44v6. The pooled analyses of 9 studies showed that CD44v6 expression in gastric cancer (758 patients and 621 controls) was significantly higher compared to controls (OR  = 82.673, 95% CI  = 44.980--151.953, P\<0.001) ([Table 3](#pone-0091842-t003){ref-type="table"}). CD44v6 overexpression was associated with a higher risk of death at 5 years in 5 studies (767 patients; RR  = 1.901, 95% CI  = 1.432--2.525, P\<0.001) ([Fig. 4](#pone-0091842-g004){ref-type="fig"}, [Table 3](#pone-0091842-t003){ref-type="table"}). Of the tumor-related factors, increased depth of invasion (10 studies, 932 patients; OR  = 2.251, 95% CI  = 1.415--3.582, P = 0.001), lymph node metastasis (12 studies, 1149 patients; OR  = 3.027, 95% CI  = 2.313--3.962, P\<0.001), distant metastasis (5 studies, 578 patients; OR  = 3.431, 95% CI  = 2.157--5.456, P\<0.001), vascular invasion (6 studies, 753 patients; OR  = 1.926, 95% CI  = 1.170--3.171, P = 0.01), histological differentiation (8 studies, 573 patients; OR  = 1.704, 95% CI  = 1.193 2.434, P = 0.003), and TNM stage (7 studies, 589 patients; OR  = 3.918, 95% CI  = 2.658--5.777, P\<0.001) provided remarkable prognostic information ([Table 3](#pone-0091842-t003){ref-type="table"}).

![Meta-analysis on the relation between CD44v6 expression and 5-year overall survival (OS).\
The summary RR and 95% CIs were shown (random-effect model analysis).](pone.0091842.g004){#pone-0091842-g004}
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###### Meta-analyses of Surviving and Cd44v6 expressions on gastric cancer.

![](pone.0091842.t003){#pone-0091842-t003-3}

  Stratification of gastric cancer    Surviving   CD44v6                                                                                                                                                  
  ---------------------------------- ----------- -------- ------ -------- ---------------------------- ------- -------- ------- ------- ---- ------ -------- --------------------------- ------- -------- -------
  Case-Control                          China       8      828    Fixed     60.162 (32.857--110.159)    0.000   20.10%   0.011   China   6    715    Fixed    45.271 (21.598 --94.889)    0.000   0.00%   
                                        Japan       1      348      \-     184.406 (11.290--3011.948)   0.000     .%             Japan   2    466    Fixed    220.330 (52.955--916.733)   0.000   0.00%   
                                        Korea       2      526    Fixed    212.274 (29.119--1547.435)   0.000   0.00%            Korea   1    198      \-     82.673 (44.980--151.953)    0.000     .%    
                                         All        11     1702   Fixed     83.622 (46.476--150.455)    0.000   20.40%            All    9    1379   Fixed    82.673 (44.980--151.953)    0.000   31.50%   0.135
  Overall 5-year survival               China       4      371    Fixed       1.731 (1.380--2.172)      0.000   0.00%    0.008   China   2    198    Fixed      1.748 (1.060--2.884)      0.029   71.00%  
                                        Japan       \-      \-      \-                 \-                \-       \-             Japan   2    336    Random     1.884 (1.048--3.386)      0.034   75.20%  
                                        Korea       2      263    Fixed       1.500 (1.194--1.885)      0.001   0.00%            Korea   1    233      \-       2.640 (1.502--4.639)      0.001     .%    
                                         All        6      634    Fixed       1.627 (1.384--1.913)      0.000   0.00%             All    5    767    Random     1.901 (1.432--2.525)      0.000   57.80%   0.282
  The depth of invasion                 China       6      584    Fixed       1.663 (0.751--3.682)      0.21    79.70%   0.027   China   6    381    Fixed      3.183 (1.879--5.390)      0.000   9.70%   
                                        Japan       2      309    Fixed       0.626 (0.378--1.036)      0.069   0.00%            Japan   4    551    Fixed      1.599 (0.887--2.883)      0.119   56.10%  
                                        Korea       3      1339   Fixed       1.250 (0.387--4.043)      0.709   91.50%           Korea   \-    \-      \-                \-                \-       \-    
                                         All        12     2232   Fixed       1.292 (0.754--2.214)      0.352   84.30%            All    10   932    Random     2.251 (1.415--3.582)      0.001   51.9%    0.083
  Lymph node status                     China       8      736    Fixed       1.764 (0.743--4.190)      0.198   83.50%   0.083   China   7    499    Fixed      4.219 (2.807--6.343)      0.000   0.00%   
                                        Japan       3      438    Fixed       0.963 (0.636--1.459)      0.859   0.00%            Japan   4    551    Fixed      2.182 (1.486--3.205)      0.000   44.10%  
                                        Korea       3      1339   Fixed       1.245 (0.602--2.572)      0.554   80.40%           Korea   1     99      \-       3.676 (1.232--10.963)     0.020     .%    
                                         All        14     2500   Fixed       1.429 (0.909--2.247)      0.121   80.60%            All    12   1149   Fixed      3.027 (2.313--3.962)      0.000   33.60%   0.045
  Distant metastasis                    China       3      317    Fixed       2.293 (1.212--4.340)      0.011   62.60%   0.300   China   3    259    Fixed      3.248 (1.654--6.378)      0.001   0.00%   
                                        Japan       \-      \-      \-                 \-                \-       \-             Japan   2    319    Fixed      3.621 (1.918--6.836)      0.000   64.20%  
                                        Korea       1      106      \-        1.000 (0.325--3.079)      1.000     .%             Korea   \-    \-      \-                \-                \-       \-    
                                         All        4      423    Fixed       1.901 (1.101--3.280)      0.021   53.20%            All    5    578    Fixed      3.431 (2.157--5.456)      0.000   0.00%    0.138
  TNM stage                             China       5      414    Random      3.206 (1.338--7.680)      0.009   74.10%   0.861   China   5    355    Fixed      5.467 (3.289--9.087)      0.000   23.70%  
                                        Japan       \-      \-      \-                 \-                \-       \-             Japan   1    135      \-       2.103 (0.963--4.593)      0.062     .%    
                                        Korea       1      106      \-        3.202 (1.448--7.084)      0.004     .%             Korea   1     99      \-       3.063 (1.144--8.201)      0.026     .%    
                                         All        6      520    Random      3.215 (1.624--6.364)      0.001   67.60%            All    7    589    Fixed      3.918 (2.658--5.777)      0.000   35.80%   0.073
  Vascular invasion                     China       1       97      \-        1.378 (0.499--3.806)      0.536     .%     0.141   China   1    103      \-       2.945 (0.996--8.711)      0.051     .%    
                                        Japan       2      309    Fixed       0.637 (0.382--1.063)      0.085   0.00%            Japan   4    551    Random     1.771 (0.877--3.576)      0.111   69.10%  
                                        Korea       1      157      \-        0.779 (0.292--2.075)      0.617     .%             Korea   1     99      \-       1.892 (0.712--5.026)      0.201     .%    
                                         All        4      563    Fixed       0.753 (0.500--1.134)      0.174   0.00%             All    6    753    Fixed      1.926 (1.170--3.171)      0.010   51.40%   0.632
  Histological differentiation          China       8      746    Fixed       0.829 (0.494--1.391)      0.478   61.90%   0.347   China   7    438    Fixed      1.845 (1.217--2.796)      0.004   30.00%  
                                        Japan       1      135      \-        0.256 (0.109--0.600)      0.002     .%             Japan   1    135      \-       1.362 (0.678--2.736)      0.386     .%    
                                        Korea       1      157      \-        0.796 (0.418--1.515)      0.487     .%             Korea   \-    \-      \-                \-                \-       \-    
                                         All        10     1038   Fixed       0.730 (0.460--1.158)      0.181   65.00%            All    8    573    Fixed      1.704 (1.193--2.434)      0.003   22.9%    0.534
  Size                                  China       4      438    Fixed       1.049 (0.713--1.544)      0.808   0.00%    0.635   China   \-    \-      \-                \-                \-       \-    
                                        Japan       \-      \-      \-                 \-                \-       \-             Japan   \-    \-      \-                \-                \-       \-    
                                        Korea       2      263    Fixed       2.876 (1.702--4.860)      0.000   0.00%            Korea   \-    \-      \-                \-                \-       \-    
                                         All        6      701    Fixed       1.508 (1.110--2.048)      0.009   49.20%            All    \-    \-      \-                \-                \-       \-      \-
  Sex                                   China       7      688    Fixed       1.029 (0.735--1.441)      0.868   0.00%    0.548   China   3    147    Fixed      0.737 (0.343--1.582)      0.433   15.50%  
                                        Japan       2      252    Fixed       1.985 (1.118--3.522)      0.019   34.70%           Japan   2    223    Fixed      0.827 (0.459--1.489)      0.526   0.00%   
                                        Korea       2      263    Fixed       0.815 (0.486--1.367)      0.439   26.50%           Korea   \-    \-      \-                \-                \-       \-    
                                         All        11     1203   Fixed       1.103(0.856--1.420)       0.448   8.00%             All    5    370    Fixed      0.792 (0.497--1.263)      0.327   0.00%    0.909
  Age                                   China       5      487    Fixed       0.797 (0.550--1.156)      0.232   0.00%    0.778   China   3    144    Fixed      1.478 (0.685--3.187)      0.319   0.00%   
                                        Japan       3      426    Fixed       1.013 (0.668--1.535)      0.952   0.00%            Japan   1    135      \-       0.948 (0.471--1.906)      0.880     .%    
                                        Korea       2      263    Fixed       1.291 (0.787--2.115)      0.312   0.00%            Korea   \-    \-      \-                \-                \-       \-    
                                         All        10     1176   Fixed       0.970 (0.762--1.234)      0.803   0.00%             All    4    279    Fixed      1.160 (0.693--1.940)      0.572   0.00%    0.433

NS, number of studies, NP, number of patients; OR, odd ratio; RR, risk ratio; CI, confidence interval.

### Correlation of Survivin expression with prognosis {#s3c6}

Compared to normal controls, the overexpression of Survivin was associated with worse outcome in gastric cancer among 11 studies (863 patients and 839 controls; OR  = 83.622, 95% CI  = 46.476--150.455, P\<0.001) ([Table 3](#pone-0091842-t003){ref-type="table"}). This result from the pooled estimate was statistically significant for detrimental 5-year overall survival in 6 studies (634 patients; RR  = 1.627, 95% CI  = 1.384--1.913, P\<0.001) ([Fig. 5](#pone-0091842-g005){ref-type="fig"}, [Table 3](#pone-0091842-t003){ref-type="table"}). Reduced survival was heavily influenced by tumor size (6 studies, 701 patients; OR  = 1.508, 95% CI  = 1.110--2.048, P  = 0.009), distant metastasis (4 studies, 423 patients; OR  = 1.901, 95% CI  = 1.101--3.280, P = 0.021), and TNM stage (6 studies, 520 patients; OR  = 3.215, 95% CI  = 1.624--6.364, P  = 0.001) ([Table 3](#pone-0091842-t003){ref-type="table"}).

![Meta-analysis on the relation between Survivin expression and 5-year overall survival (OS).\
The summary RR and 95% CIs were shown (fixed-effect model analysis).](pone.0091842.g005){#pone-0091842-g005}

Sensitivity analysis and publication bias {#s3d}
-----------------------------------------

In the present study, sensitivity analysis indicated that the pooled RR (or OR) was not significantly influenced by omitting any single study at a given time. In addition, the results showed there was no evidence of publication bias for most subgroup analyses ([Table 2](#pone-0091842-t002){ref-type="table"} and [3](#pone-0091842-t003){ref-type="table"}). However, the potential biases observed for depth of invasion for the HIF-1α group (P~bias~  = 0.017), case-control study (P~bias~  = 0.034) and overall survival (P~bias~  = 0.006) for the PTEN group, and case-control study (P~bias~  = 0.011), depth of invasion (P~bias~  = 0.027), and overall survival (P~bias~  = 0.008) for the Survivin group could be ruled out by Begg\'s and Egger\'s tests ([Table 2](#pone-0091842-t002){ref-type="table"} and [3](#pone-0091842-t003){ref-type="table"}).

Discussion {#s4}
==========

Almost two-thirds of the world\'s gastric cancer cases occur in Asia (China, Japan, and Korea) [@pone.0091842-Shin1]. The mortality of cancer patients is largely caused by metastases rather than their primary tumors at the time of diagnosis. Therefore, identifying the risk of disease recurrence and mortality in gastric cancer patients is critical to monitor patients and select appropriate adjunctive therapies in clinical practice [@pone.0091842-Shah1], [@pone.0091842-MezaJunco1]. However, useful biomarkers for predicting the prognosis of gastric cancer patients have not been well studied. Here, we introduced one subset of potential clinically useful biomarkers, HIF-1a/PTEN/CD44v6/Survivin, and precisely estimated their prognosis and clinicopathological significance.

Mounting evidence suggests that hypoxic tumor microenvironments, especially the overexpression of HIF-1a, are strongly implicated as the hallmark of a wide variety of human malignancies [@pone.0091842-Hill1], [@pone.0091842-Zhao1]. When activated by the novel tumor suppressor gene PTEN [@pone.0091842-Lu1], [@pone.0091842-Park1], HIF-1α can transcriptionally regulate a host of hypoxia-responsive molecules that contribute to drug resistance, epithelial-mesenchymal transition, survival, angiogenesis, and metastasis [@pone.0091842-Semenza2], [@pone.0091842-Tsai1], [@pone.0091842-Krishnamachary1], [@pone.0091842-Rohwer1], [@pone.0091842-Lanvin1], including inducers of angiogenesis (e.g., VEGF), proliferation of regulatory proteins (e.g., Survivin), and mediators of metastasis (e.g., CD44v6, MMP, E-cadherin). In this study, we found that the overexpression of HIF-1α occurred at a median frequency of 54.1% in gastric cancer. Patients who expressed high levels of HIF-1α were associated with a worse outcome, with a pooled risk for overall survival (RR  = 1.508) that was similar to that obtained in a recently published study on hepatocellular carcinoma (HR  = 1.65) [@pone.0091842-Zheng1]. Moreover, aberrant expression of PTEN, CD44v6, and Survivin were also observed in tumors correlating with poor overall survival, with risk of death at 5 years of 1.637, 1.901, and 1.627, respectively ([Table 2](#pone-0091842-t002){ref-type="table"} and [3](#pone-0091842-t003){ref-type="table"}). Subgroup analysis confirmed that the reduced survival was significantly correlated with increased dedifferentiation, tumor size, advanced tumor invasion, lymph node spread, distant metastasis, vascular invasion, and higher TNM stage, indicating increased biological aggressiveness and a greater possibility of systemic diffusion.

Gastric tumors can trigger the substantial development of new blood vessels for tumor growth, maintenance, and metastasis [@pone.0091842-Hanahan1], [@pone.0091842-Chen1]. The high proliferation of tumor cells can induce local hypoxia, which is a strong stimulus for HIF-1α. Loss of PTEN in gastric cancer promotes tumor angiogenesis and invasion by increasing expression of VEGF through the increase of the HIF-1α protein level, which is an active process that requires the degradation of the extracellular matrix, the increase of microvascular permeability both in the blood and lymphatic vessels, and interstitial fluid pressure (IFP) [@pone.0091842-Sullivan1], favoring the progression of the intravasation and extravasation of tumor cells. This may offer a possible explanation for the observed strong statistical association of HIF-1α overexpression with advanced tumor invasion, lymph node spread, vascular invasion, and distant metastasis. Recent studies have shown that the percentage of CD44 positive cells expressing variant exons v6 (CD44v6) in tumor cells could be significantly increased by HIF-1α-mediated transcription under hypoxic conditions [@pone.0091842-Krishnamachary2]. CD44v6, one cell adhesion molecule, has been proposed to function in the homing of lymphocytes, extracellular matrix binding, cell migration, and invasion. Therefore, a high level of CD44v6 expression may also contribute to the aggressive phenotype. In addition, the upregulation of Survivin by HIF-1α and PTEN contributed to cisplatin (CDDP) resistance, indicating that inhibition of these pathways may be a potential strategy for overcoming CDDP resistance in the treatment of gastric cancer [@pone.0091842-Sun1].

These analyses have several important implications. First, we show that the abnormal expression of HIF-1α/PTEN/CD44v6/Survivin is associated with worse outcome, which suggests that each protein may be a useful therapeutic target for drug development. Currently, some clinical trials targeting HIF-1α/PTEN/Survivin at different phases are being developed, which will likely benefit populations with certain conditions (<http://www.clinicaltrials.gov>) ([Table 4](#pone-0091842-t004){ref-type="table"}). Second, the analyses highlight the importance of developing multiple biomarkers for monitoring treatment response, clinical uses of HIF-1α inhibitors, and prognosis assessment. We have also noticed several new-ly-publicated meta analyses of estimating prognostic value of either HIF-1α or Survivin on gastric cancer patient [@pone.0091842-Zhu1], [@pone.0091842-Zhang1], [@pone.0091842-Liu1], [@pone.0091842-Krieg1]. Among them, three quarters of electronic databases were used to identify published studies before December, 2012, with the combined HR \<2. Because hypoxia is likely to have complex, and even opposing, effects during different stages of tumor development [@pone.0091842-Lu1], [@pone.0091842-Semenza1], any single molecule cannot be used to independently predict the full prognosis of patients. Combinations of proteins involved in HIF-1α regulation of the metastasis cascade should provide increased prognostic power over individual markers themselves. Moreover, systematically assessing the main prognostic factors in gastric cancer, both tumor- and patient-related, may also have meaningful impacts at the time of diagnosis or surgical treatment, including the depth of tumor invasion, lymph node spread, venous invasion, TNM stage, differentiation, tumor size, as well as sex and age. In present study, the most key results of the meta-analysis of clinical variables among Asian patients showed a magnitude of effect size of OR \>2, and in some cases \>3. As a rule of the thumb, a prognostic factor with RR (or OR) \>2 is considered to be of useful practical value [@pone.0091842-Hayes1]. Therefore, we believe our results will provide more useful and precise information for clinical decision-making regarding gastric cancer. Third, as shown by our previous reports, VEGF appears to be a significant prognostic factor for hematogenous metastasis of gastric cancer (RR  = 2.45, P = 0.000) [@pone.0091842-Hayes1], [@pone.0091842-Chen2]. In addition, we have proposed three other genes, E-cadherin, Stat3, and MMP-9, as prognosis biomarkers of tumor metastasis. Therefore, analyses combining previous results may show a possible axis of action by HIF-1α and its oncogenic signaling pathway ([Fig. 6](#pone-0091842-g006){ref-type="fig"}), which could contribute to improvements in prognosis assessment, functional analysis, and drug-targeted therapy in the prevention and treatment of gastric cancer. From this perspective, we believe that our meta-analysis does indeed present positive significance and novelty.

![Hypoxia regulation of the metastasis cascade.](pone.0091842.g006){#pone-0091842-g006}

10.1371/journal.pone.0091842.t004

###### Ongoing studies evaluating anti- HIF-1α/PTEN/Survivin therapeutic strategies.

![](pone.0091842.t004){#pone-0091842-t004-4}

                         Study/sponsor                                                  Phase/setting                                                                Experimental arm(s)
  --------------- --------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------
  Anti- HIF-1α            NCT01120288                                 Liver Metastases; Phase 1;Active, not recruiting                                                     EZN-2968
                          NCT01763931                            Newly Diagnosed Operable Breast Cancer; Phase 2; Recruiting                                               Digoxin
                          NCT00522652                                Advanced Solid Tumors; Lymphoma; Phase 1; Completed                                                    PX-478
                          NCT01047293                                   Colorectal Carcinoma; Phase 1--2; Recruiting                                             RAD001; FOLFOX; Bevacizumab
                          NCT00117013                     Refractory Advanced Solid Neoplasms Expressing HIF-1a; Phase 1; Completed                       Topotecan; Fluorine-19-Fluoroded Xyglucose
                          NCT00880672                                 Benign Prostatic Hyperplasia; Phase 4; Completed                                                   Dutasteride
                          NCT01251926                             Refractory Solid Tumors; Phase 1; Active, not recruiting                                          EZN-2208; Bevacizumab
                          NCT01206764                                Advanced Renal Cell Carcinoma; Phase 4; Recruiting                                                     RAD001
                          NCT01814449                                          Human Breast Cancer; Recruiting                                                  18FMISO PET/CT scan; Letrozole
                          NCT00389805                 Advanced Non-Small Cell Lung Cancer or Other Solid Tumors; Phase 1--2; Completed                          bortezomib;pemetrexed disodium
                   MD Anderson Cancer Center                              Advanced malignancies; Phase I; Completed                                bevacizumab and temsirolimus plus liposomal doxorubicin
  Anti-PTEN               NCT01283035          Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer; Phase 2; Recruiting                              MK2206
                          NCT00490139                                        Breast Cancer; Phase 3; Recruiting                                                     Lapatinib;Trastuzumab
                          NCT00499603                                         Breast Cancer; Phase 2; Completed                                  Paclitaxel;5-Fluorouracil;Epirubicin;Cyclophosphamide;RAD001
                          NCT01042925                                       Breast Cancer; Phase 1--2; Completed                                                XL147 (SAR245408); paclitaxel
                          NCT01013324                                      Endometrial Cancer; Phase 2; Completed                                                     XL147 (SAR245408)
                          NCT00387894                       Recurrent Glioblastoma Multiforme or Gliosarcoma; Phase 2; Completed                                    Bevacizumab; Erlotinib
                          NCT01550380                Advanced, Metastatic, or Recurrent Endometrial Cancer; Phase 2; Not yet recruiting                                     BKM120
                          NCT00301418           Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma; Phase 1--2; Recruiting                             Erlotinib
                          NCT00895960                   Glioblastoma; CNS Disease; Brain Diseases; Phase 1--2; Active, not recruiting                  Dasatinib; RT (Radiotherapy); TMZ (Temozolomide)
  Anti-Survivin           NCT01088035                                          Ependymoma; Phase 2; Recruiting                                                           Carboplatin
                          NCT00537121                             Esophageal Cancer; Gastric Cancer; Liver Cancer; Phase 1                             Vorinostat, Irinotecan, Fluorouracil, Leucovorin

There are also limitations that should be noted based on the present analysis. First, because this is a literature-based analysis from which predominantly positive results were published, our estimate for the association between HIF-1α/PTEN/CD44v6/Survivin and poor outcome might be inflated. Therefore, the discrepancies in the conclusions of various studies encouraged researchers to publish their data regardless of the significance of their results, which may limit the publication bias. In the present study, we placed emphasis on assessing biases across studies and pinpointing any potential sources of heterogeneity. Subgroup analyses by ethnicity and clinical variables were also performed. We comprehensively assessed the publication biases by using Begg\'s and Egger\'s tests and did not detect any significant deviation among most studies, except for the several factors mentioned in the "Results" section. In view of this, we are confident that the results of our meta-analysis are reliable. In addition, we could not pool the hazard ratios of death because of a lack of time-to-death data. We only figured out the risk ratio of death at fixed time points. Although this measure is less robust because it does not consider the duration of survival until death, this is the only feasible method of the data available [@pone.0091842-Ocana1].

In conclusion, our analyses show that the aberrant expression of HIF-1α, PTEN, CD44v6, and Survivin, as measured by IHC, may predict the 5-year overall survival risk and potential for invasion and metastasis in gastric cancer patients, particularly in Asian patients. These data suggest that the development of strategies against this subset of proteins could lead to a reasonable therapeutic treatment program for gastric cancer. However, further large sample and non-Asian population-based studies are required.
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